Does Thromboprophylaxis During Pregnancy Lower Risk for Adverse Outcomes?

Genetic and acquired thrombophilias have been associated with adverse pregnancy outcomes and venous thromboembolism (VTE) during pregnancy and postpartum. Now, researchers have conducted an international, randomized, controlled trial to examine whether antepartum treatment with dalteparin, a low-molecular-weight heparin (LMWH), can lower risks for VTE, severe preeclampsia, small-for-gestational-age births, or pregnancy loss in women with thrombophilia and histories of adverse pregnancy events or high risk for VTE.

In all, 292 participants were randomized to no treatment or LMWH from <21 weeks' gestation through delivery. Neither the incidence of the primary composite outcome nor any of its components differed between groups; however, minor b…